Literature DB >> 21711974

Recombinant marker allergens in diagnosis of patients with allergic rhinoconjunctivitis to tree and grass pollens.

Martin Canis1, Moritz Gröger, Sven Becker, Christine Klemens, Matthias F Kramer.   

Abstract

BACKGROUND: The aim of this study was to investigate recombinant marker allergens in patients with allergic rhinoconjunctivitis to tree and grass pollens.
METHODS: Sera of 260 tree pollen- and 282 grass pollen-allergic patients were analyzed. Bet v 1 and Phl p 1/p 5 were used as marker allergens for allergies to pollen from birch and grasses. Profilin (Bet v 2 and Phl p 12) and calcium-binding protein (Bet v 4 and Phl p 7) were used as markers for polysensitization.
RESULTS: Two hundred thirty-nine (92%) patients tested positive for IgE anti-Bet v 1. All of them were positive for IgE antibodies against natural birch extract (t3), hazel (t4), and alder (t2). Bet v 1 in combination with t3 identified allergies from related trees with a sensitivity of 99.2%. Two hundred fifty-six patients (91%) tested positive for IgE anti-Phl p 1 and/or anti-Phl p 5. All of them were positive for IgE antibodies against natural timothy (g6) and rye (g12) extract. Phl p 1/p 5 and natural timothy extract identified allergies from grasses and rye with a sensitivity of 99.3%. All Patients reacting to the cross-reactive allergens Bet v 2, Phl p 12, Bet v 4, and Phl p 7 were polysensitized.
CONCLUSION: Bet v 1 in combination with natural birch pollen extract identifies allergies from related trees with a sensitivity of 99.2%. Phl p 1, Phl p 5, and natural timothy extract identifies allergies from grasses and rye in 99.3%. Reactivity to the allergens Bet v 2, Phl p 12, Bet v 4, and Phl p 7 identifies polysensitization and cross-reactivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21711974     DOI: 10.2500/ajra.2011.25.3551

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  8 in total

Review 1.  [Molecular component-resolved allergy diagnostics in ENT].

Authors:  L Klimek; S Becker
Journal:  HNO       Date:  2017-10       Impact factor: 1.284

Review 2.  Molecular biomarkers for grass pollen immunotherapy.

Authors:  Florin-Dan Popescu
Journal:  World J Methodol       Date:  2014-03-26

Review 3.  Overview of component resolved diagnostics.

Authors:  Regina Treudler; Jan C Simon
Journal:  Curr Allergy Asthma Rep       Date:  2013-02       Impact factor: 4.806

4.  Polysensitisation to pollen due to profilin and calcium-binding protein: distribution of IgE antibodies to marker allergens in grass and birch pollen allergic rhinitis patients in southern Germany.

Authors:  G Muehlmeier; H Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-07-02       Impact factor: 2.503

Review 5.  Personalized Medicine in Allergic Asthma: At the Crossroads of Allergen Immunotherapy and "Biologicals".

Authors:  Benedikt Fritzsching
Journal:  Front Pediatr       Date:  2017-02-17       Impact factor: 3.418

6.  Birch Pollen Related Pear Allergy: A Single-Blind Oral Challenge TRIAL with 2 Pear Cultivars.

Authors:  Nicolette W de Jong; Severina Terlouw; Frank E van Boven; M S van Maaren; Marco W J Schreurs; Dianne B P M van den Berg-Somhorst; Diederik Esser; Shanna Bastiaan-Net
Journal:  Nutrients       Date:  2021-04-18       Impact factor: 5.717

7.  A Multicenter Study Assessing Risk Factors and Aeroallergens Sensitization Characteristics in Children with Self-Reported Allergic Rhinitis in China.

Authors:  Liting Wu; Wenting Luo; Haisheng Hu; Xianhui Zheng; Zhangkai J Cheng; Dongming Huang; Xiaowen Huang; Hong Zhang; Yang Liu; Rongfang Zhang; Hui Yang; Yun Sun; Yi Wang; JinHai Ma; Jing Liu; Xin Sun; Huajie Wu; Chunhua Wei; Shuping Zhang; Xiaoluan Li; Shuang Ren; Chuangli Hao; Baoqing Sun
Journal:  J Asthma Allergy       Date:  2021-12-07

8.  In vivo Induction of Functional Inhibitory IgG Antibodies by a Hypoallergenic Bet v 1 Variant.

Authors:  Lorenz Aglas; Athanasios Bethanis; Paulina Chrusciel; Frank Stolz; Melanie Gruen; Ulla-Marjut Jaakkola; Laurian Jongejan; Emrah Yatkin; Ronald Van Ree
Journal:  Front Immunol       Date:  2020-09-03       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.